Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as an alternative treatment for patients with advanced head and neck squamous cell carcinoma (HNSCC) who do not respond to conventional treatments. Together with ICIs, radiotherapy plays an important role in activating the immune system against tumors, proving to be effective in treating these tumors. It is therefore necessary t…